Biomarker Development in Advanced Prostate Cancer- Alicia Morgans
November 29, 2017
Alicia Morgans, MD presents on the topic of biomarker development in advanced prostate cancer. In her presentation, Dr. Morgans discusses the difference between predictive and prognostic biomarkers and the importance of understanding the purpose of each. Also, Dr. Morgans identifies clinical biomarkers for men with mCRPC who are undergoing treatment with docetaxel. Listeners will learn the prognostic implications of circulating tumor cells (CTCs) and AR-V7 expression in these cells. In conclusion, Dr. Morgans will explain the potential use of Basal vs. Luminal A vs. Luminal B subtypes in predicting outcomes with androgen deprivation therapy (ADT).
Alicia Morgans, MD, MPH
Related Content Reviewed in Discussion:
Using Clues from Studies of Genomic Evolution to Develop Clinically Applicable Biomarkers
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer - Abstract
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomised phase 3 trial - Abstract
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.